Zinc increases the effects of essential amino acids-whey protein supplements in frail elderly by Rodondi, A. et al.
The Journal of Nutrition, Health & Aging©
Volume 13, Number 6, 2009
491
Introduction
Undernutrition, particularly protein deficiency, is often
encountered in the elderly population (1, 2). Whilst a reduction
in caloric intake may accompany the decrease in energy
expenditure in the elderly, it appears that sufficient protein
intakes are mandatory for bone health (3). A concurrent
reduction of dietary protein with aging could be detrimental for
the preservation of bone integrity. A variety of cross-sectional
and longitudinal studies have shown a positive association
between bone mineral mass and dietary protein intake (4-8).
Dietary proteins influence both the production and action of
IGF-I and thereby the effect of IGF-I on bone anabolism (3, 9,
10). In preclinical studies, an isocaloric low protein diet
decreases areal bone mineral density (BMD) at the levels of
skeletal sites formed by trabecular and cortical bone (11, 12),
alters trabecular microarchitecture, renders bone cortices
thinner (13) and modifies intrinsic bone tissue quality as
evaluated by a nanoindentation test (14). These various changes
result in a decrease of bone strength. In humans, these
alterations could contribute to an increased fracture risk (3, 15). 
In terms of molecular mechanisms, an isocaloric low protein
diet is associated with increased bone resorption and decreased
bone formation, reduced IGF-I production, and an
accompanying resistance of bone to the effects of both IGF-I
and growth hormone (16, 17). An altered gonadotrop axis in
both males and females has also been documented (11, 12). The
bone catabolic effects of an isocaloric low protein diet seem to
be a TNF-alpha-dependent process (18).
Protein repletion corrects the alterations caused by protein
undernutrition. Indeed, in elderly patients with a recent hip
fracture, protein supplements decrease the rates of medical
complications (19, 20), reduce accelerated bone loss (21, 22),
and lower the duration of stay in rehabilitation care facilities by
25% (21). These observations have been associated with an
increase in circulating serum IGF-I levels. In preclinical
studies, isocaloric essential amino acid supplements correct
bone mechanical properties by improving microarchitecture
(connectivity and cortical thickness), and intrinsic bone tissue
quality (13, 14). The correction of protein deficiency also
reverses the alterations in both the somatotrop and gonadotrop
axes, and in bone remodeling. 
Zinc is known to play a role in IGF-I production (23, 24).
Circulating levels of IGF-I increase with dietary zinc
supplementation (25, 26). Growth retardation related to zinc
deficiency is associated with low serum IGF-I concentrations,
inhibition of the anabolic actions of IGF-I (27) and with a
decreased expression of the IGF-I and GH receptor genes (27,
28). A meta-analysis of 25 studies investigating the effects of
zinc supplementation on growth in prepubertal children showed
a highly statistically significant effect on linear growth and
weight gain (29). On the other hand, decreased zinc reserves
are observed in undernourished subjects (30, 31). The presence
of zinc inhibits the stimulatory effect of regucalcin, a regulatory
protein involved in intracellular signalling on osteoclast-like
cell formation (32). Several studies have shown that zinc has a
distinct effect on bone metabolism by inhibiting bone
resorption and stimulating bone formation (32-36).
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The relationship between zinc status and IGF-I in the elderly
has not been established, although the correlation between
serum IGF-I concentrations and zinc intake was significantly
better than that with protein intake or age in a group of healthy
community-dwelling post-menopausal women (24).
In the present study, we assessed the effect of zinc
supplements on circulating IGF-I levels, bone remodeling and
physical performance responses to protein repletion in
undernourished, elderly patients. The results indicate that zinc
supplementation accelerates the serum IGF-I response to
essential amino acids-whey protein administration, and is
associated with a decrease in the serum levels of a biochemical
marker of bone resorption and improved functional
performance.  
Patients and methods
Patients
Within one week after admission to a tertiary care geriatric
hospital, elderly patients of both sexes were recruited between
October 1999 and August 2001. Admissions were due to
cardiovascular and lung diseases (27%), osteoarticular
disorders (16%), infections (13%), neurological diseases (10%),
falls, psychiatric disorders or skin diseases (34%). Inclusion
criteria consisted of ability to give a written, informed consent
and a mini nutritional assessment score between 17 and 24
(corresponding to a failure to thrive category) (37). Exclusion
criteria were: severely decompensated cardiac, pulmonary,
renal (creatinine clearance <30 ml/min) or hepatic failure;
major mental impairment (minimal mental state score <17),
urine incontinence, inflammatory syndrom (C-reactive protein
>15mg/l), bedridden, corticosteroids at a dose greater than 7.5
mg/day prednisone-equivalent, life expectancy estimated as
shorter than one month. All patients were given a daily 20 g
oral protein supplement containing 15g whey protein and 5g
essential amino acids (in a proportion similar to that found in
casein), and 550mg calcium (provided by Novartis Nutrition,
Berne, Switzerland). The protein supplement was administered
in the evening preferentially, or fractionated throughout the
day, for a period of 4 weeks. Using a random number table, the
patients were assigned to 30mg/day oral zinc directly added to
the protein supplements powder, or no addition, on a strict
double-blind basis. Non compliance was defined by
consumption of less than 50% of the powder. The patients were
stratified into two arms according to baseline serum albumin
levels, with a limit between strates of 30 g/l in a fully hydrated
state. A group of 8 patients fulfilling the same inclusion and
exclusion criteria, but who did not want to participate in an
intervention study, were followed at a 4-week interval.
Clinical data
We evaluated clinical status, dietary intakes, activities of
daily living (38) and medical treatments at baseline (within one
week after admission), and after 1, 2 and 4 weeks of nutritional
supplementation. Compliance, incidence of medical
complications and side effects of treatment (diarrhea, nausea),
and length of hospital stay were recorded.
Biochemical analysis
Fasting venous blood and second voiding urine samples
were collected at baseline, and after 1, 2 and 4 weeks of
nutritional supplements. Radioimmunoassays, immuno-
radiometric assays and enzyme-linked immunoassay were used
to measure calcidiol (Incstar Corp, Stillwater, MN), intact
parathormone (Nichols institute, San Juan Capistrano, CA),
IGF-I after acid-ethanol extraction (Nichols institute, San Juan
Capistrano, CA), IGF-binding protein-3 (DSL, Webster,
Texas), osteocalcin (Cis-Bio, Gif-sur-Yvette, France), and
CrossLapsTM (Roche-diagnostic, Lucerne, Switzerland).
Calcitriol was determined using a protein-binding assay (Incstar
Corp, Stillwater, MN). Albumin, protein, total calcium,
phosphate, creatinine and C-reactive protein were measured
using routine laboratory methods. Ionized calcium was
measured using a specific electrode. Zinc was determined using
the Randox colorimetric method (automate COBAS INTEGRA
700, Roche-diagnostic). Differential white cell counts were
determined at weeks 0, 1, 2, and 4. Renal tubular transports of
calcium and phosphate were measured with fasting serum and
urine values, using nomograms as previously described (39,
40).
Statistical analysis
Values are means ± SEM. Level of significance was
evaluated using an unpaired two-tailed student t-test, when two
groups were compared, an ANOVA for repeated measurements
was used to evaluate evolution over time and a Wilcoxon rank
test was employed as an alternative to the paired student t-test
to compare two groups, when the values were not normally
distributed. 
Results
Trial outline
We recruited 61 patients into this randomized, double-blind
trial and 8 untreated controls. During the 28-day intervention
period, 14 (23%) patients dropped out, 12 due to nausea, low
compliance, refusal to pursue the trial at home and 2 deaths
(one at home from bronchopneumonia and one in hospital from
bronchoaspiration). For the final analysis, 47 patients and 5
untreated controls were available (Fig.1). Twenty-seven
patients returned home before the end of the study. Blood and
urine samples were collected in their private accommodation.
Baseline characteristics
85% of enrolled patients were women and the mean age was
85.0 ± 7.4 years (mean ± SD, range: 66.7 to 105.8). The
different diagnoses were equally distributed in both groups
(data not shown). Baseline characteristics were similar in the
randomized groups (Table 1). Dietary energy intake was 1228
± 7.0 Kcal/day (5140 KJ) with 43 ± 3 g/day protein,
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representing 0.77 ± 0.03 g/kg BW, with no differences between
the two supplemented groups. Body mass index was
significantly higher in the untreated controls. Whilst there were
no differences in biochemical baseline characteristics, including
zinc levels, between the patients in the randomized controlled
trial and the untreated controls, the group with zinc
supplements had a higher serum level of calcidiol (p=.029) than
the group without zinc (Table 2). Except mean serum albumins
which were below the lower limit of normal range, confirming
the state of malnutrition of the randomized patients, all values
were within the reference range.
Figure 1
Trial outline
Among patients admitted into a tertiary care geriatric hospital between September 1999
and August 2001, 69 patients were included in the study (61 in the randomized, double
blind trial)
Table 1
Patients Baseline Characteristics
Normal EAA / whey EAA / whey Untreated
range protein protein controls
with zinc without zinc (n=8)
(30mg/d) (n=31)
(n=30)
Age  (year) 83.6 (1.3) 86.4 (1.3) 85.0 (2.6)
F/M 25/5 27/4 7/1
Previous accommodationa 9    (30%) 13    (42%) 2    (25%)
- private accommodation 21   (70%) 18    (58%) 6    (75%)
- hospital
Biochemistry
Protein –adjusted calcium 2.2-2.6 2.42 (0.02) 2.39 (0.02) 2.32 (0.02)
(mmol/l)
Ionised calcium (mmol/l) 1.12-1.32 1.20 (0.01) 1.19 (0.01) 1.19 (0.03)
Phosphate (mmol/l) 0.80-1.30 1.02 (0.03) 1.04 (0.03) 1.00 (0.05)
Creatinine (µmol/l) 45.0-98.0 74.9 (4.8) 74.0 (4.2) 72.2 (10.7)
Albumin (g/l) 35.0-52.0 31.0 (0.7) 30.4 (0.8) 33.7 (2.7)
Protein (g/l) 61.0-82.0 64.4 (1.0) 61.9 (0.8) 66.8 (2.5)
Lymphocytes Count (G/l) 1.5 (0.1) 1.5 (0.1) 1.5 (0.2)
CRP (mg/l) 0-10 8.1 (1.6) 11.4 (2.0) 3.5 (1.6)
BRI (mmol/mmol)b 0.10-0.50 0.44 (0.07) 0.50 (0.06) 0.42 (0.15)
TmPi/GFR (mmol/l GFR)c 0.80-1.35 0.97 (0.04) 0.99 (0.05) 1.03 (0.12)
TRCaI (mmol/l GFR)d 2.40-2.90 2.67 (0.03) 2.61 (0.04) 2.60 (0.07)
Values are given as the mean (SEM), except for the previous accommodation. EAA =
Essential amino acids. a. Values are given as the absolute number (percentage); b. Bone
Resorption Index (BRI) is the fasting urinary calcium-to-creatinine ratio taken as a
reflection of net bone resorption; c. Renal tubular reabsorption of phosphate; d. Renal
tubular reabsorption of calcium index.
Effects of zinc and / or essential amino acids-whey protein
supplements on plasma IGF-I
Zinc levels increased by 57.5% (percent change from
baseline) in the zinc-supplemented group after 28 days (Table
2). IGF-I levels decreased in the untreated controls during the
4-week observation period. In contrast, IGF-I rapidly increased
in the two groups with essential amino acids-whey protein
supplementation (p=.0001) reaching a plateau by only the
second week of supplementation (Fig. 2). The addition of 30
mg/day of zinc accelerated the steep elevation of serum IGF-I,
compared to the group without zinc, with a response
significantly higher at week 1 (p=.027). At 4 weeks, there was
no difference with or without zinc addition. IGF binding
protein 3 concentrations remained constant, so that IGF-I to
IGF binding protein 3 ratio exhibited kinetics similar to that of
IGF-I alone which reflects hormone bioactivity (Table 2) (41).
Figure 2
a) b) Effects of zinc addition on the IGF-I response to essential amino acids-whey protein
supplements. The results are means SEM [absolute values a) and percent from baseline b)]
and were obtained after 1, 2 and 4 weeks of nutritional supplements containing 20 g of
protein (15g whey protein and 5 g of essential amino acids) without zinc (a: closed squares;
b: stippled columns) or with zinc (a: open squares; b: open columns). Untreated controls
are represented by triangles (a) and filled columns (b).  # p = 0.0001: ANOVA for repeated
measures; there is a significant increase overtime in both groups receiving amino acids-
whey protein; * p < 0.05 vs controls without zinc. 
c) d) Effects of zinc addition on the serum osteocalcin response to essential amino acids-
whey protein supplements. The results are means SEM [absolute values c) and percent
from baseline d)] and were obtained after 1, 2 and 4 weeks of nutritional supplements
containing 20 g of protein (15 g whey protein and 5 g of essential amino acids) without
zinc (c: closed squares; d: stippled columns) or with zinc (c: open squares; d: open
columns). Untreated controls are represented by triangles (c) and filled columns (d). 
e) f) Effects of zinc addition on the serum CrossLapsTM response to essential amino acids-
whey protein supplements. The results are means SEM [absolute values e) and percent
from baseline f)] and were obtained after 1, 2 and 4 weeks of nutritional supplements
containing 20 g of protein (15g whey protein and 5 g of essential amino acids) without zinc
(e: closed squares; f: stippled columns) or with zinc (e: open squares; f: open columns).
Untreated controls are represented by triangles (e) and filled columns (f). * p < 0.05, ** p <
0.005: ANOVA for repeated measures; it showed a significant difference between zinc
supplemented and the unsupplemented group. * p < 0.05, ** p < 0.01.
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Effects of zinc and / or essential amino acids-whey protein
supplements on biochemical markers of bone remodeling and
on calcium-phosphate metabolism
In response to essential amino acids-whey protein
supplements, the bone formation marker osteocalcin increased
in the two supplemented groups, reaching a maximum by the
second week of supplementation (Fig. 2). There was no change
in untreated controls. Zinc did not affect the osteocalcin
response to protein repletion.
The bone resorption marker CrossLapsTM increased in the
untreated controls, remained stable in the essential amino acids-
whey protein group, and significantly decreased upon zinc
supplementation (Fig. 2), with significant differences between
the two supplemented groups, detectable at just one week of
supplementation. 
Although the increase of dietary protein intake may improve
calcium intestinal absorption (42), plasma levels of parathyroid
hormone, 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin
D3 (Table 2), calcium (total, ionised and protein-adjusted),
phosphate, proteins and creatinine (data not shown) did not
change during the study and did not differ between the two
groups who received similar amount of protein and calcium.
The renal handling of calcium or of phosphate was also not
influenced. 
Effects of zinc and/or essential amino acids-whey protein
supplements on functional performances 
There was no difference in the dietary intakes recorded by
the dietician between the two groups and at the end of the
study. The number of kilocalories was, in the supplemented
group with additional zinc, 1237±126 at the beginning and
1096±133 at the end, and in the other protein supplemented
group 1219±280 and 1292±350, respectively. There was a
small but not significant decrease in spontaneous protein intake
in the supplemented group with additional zinc at the end of the
trial but without any difference comparing the two
supplemented groups. 
Functional performances were evaluated by recording the
Activity of Daily Living score (38). This index slightly
improved upon essential amino acids-whey protein
supplements, irrespective of zinc addition (Table 3). However,
in a prespecified subgroup with baseline serum albumin lower
than 30g/l, zinc significantly increased this response. Hospital
stay averaged 42.5±3.5 days and was not different among the
groups (Table 3). 
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Table 2
Changes in Biochemical Variables 
Normal Range Group D0 D7 D14 D28
Zinc (µmol/l) 10.0-23.0 prot+zn1 12.9 ± 0.8 13.5 ± 0.4  (+29.0%) 14.5 ± 1.2  (+38.4%) 16.0 ± 0.9 (+57.5%)
prot2 14.1 ± 2.7 13.4 ± 2.4  (-4.4%) 13.3 ± 2.5  (-6.5%) 14.4 ± 3.1 (+3.6%)
untreated3 NA NA NA NA
IGF-I (µg/l) 41.0-213.0 prot+zn 82.6 ± 9.0 110.3 ± 10.3 (+48.2%)# 119.3 ± 10.7 (+69.2%) 101.5## ± 11.2 (+29.2%)
prot 73.3 ± 8.3 86.6 ± 10.1 (+22.4%) 106.1 ± 21.5 (+38.7%) 107.8## ± 15.5 (+45.8%)
untreated 91.4 ± 21.5 NA NA 54.8 ± 16.8 (-16.8%)
IGF-BP3 (µg/l) prot+zn 2.2 ± 0.1 2.3 ± 0.1 (+6.5%) 2.3 ± 0.1 (+7.0%) 2.3 ± 0.1 (+7.1%)
prot 2.1 ± 0.1 2.2 ± 0.1 (+7.2) 2.3 ± 0.1 (+12.4%) 2.4 ± 0.1 (+14.6%)
untreated 1.9 ± 0.2 NA NA 1.5 ± 0.2 (-11.2%)
IGF-I / IGF-BP3 prot+zn 35.6 ± 2.5 45.9 ± 3.3 (+37.3%) 50.2 ± 4.0 (+53.4%) 41.7 ± 3.2 (+18.2%)
prot 33.6 ± 2.7 36.9 ± 3.3 (+13.1%) 41.7 ± 4.5 (+23.0%) 41.6 ±4.2 (+21.6%)
untreated 45.4 ± 8.0 NA NA 26.8 ±7.2 (-8.3%)
Osteocalcin (µg/l) 8.0-40.0 prot+zn 23.7 ± 1.7 25.3 ± 2.2 (+12.8%) 27.3 ± 2.4 (+18.3%) 25.8 ± 2.7 (+16.4%)
prot 25.4 ± 1.7 28.4 ± 2.2 (+6.0%) 30.8 ± 2.4 (+21.4%) 31.6 ± 3.4 (+21.5%)
untreated 27.4 ± 1.6 NA NA 30.0 ± 2.3 (+3.8%)
Crosslaps ™ (ng/ml) 0.50-0.92 prot+zn 0.56 ± 0.04 0.5 ± 0.04 (-10.3%) ‡ 0.46* ± 0.04 (-20.1%) ‡‡ 0.41** ± 0.04 (-21.5%) ‡‡
prot 0.60 ± 0.05 0.57 ± 0.04 (+3.9%) 0.60 ± 0.04 (+6.29%) 0.64 ± 0.06 (+6.1%)
untreated 0.43 ± 0.07 NA NA 0.68 ± 0.02 (+74.7%)
Intact PTH (pmol/l) 1.0-6.0 prot+zn 5.2 ± 0.4 NA NA 5.0 ± 0.5 (+0.4%)
prot 5.7 ± 0.7 NA NA 4.2 ± 0.4 (-14.8%)
untreated 4.3 ± 0.9 NA NA 5.3 ± 1.7 (+18.5%)
Calcidiol (nmol/l)a 20.-95.0 prot+zn 55.9 ± 5.4 NA NA 70.4 ± 6.7 (+39.1%)
prot 39.7 ± 4.9 § NA NA 56.2 ± 5.9 (+68.8%)
untreated 67.6 ± 12.4 NA NA 70.0 ± 11.5 (+20.5%)
Calcitriol (pmol/l)b 40.0-140.0 prot+zn 90.4 ± 9.7 NA NA 92.1 ± 6.6 (+17.4%)
prot 75.0 ± 8.1 NA NA 88.1 ± 6.8 (+25.5%)
untreated NA NA NA NA
All values are given as the mean ± SEM. Values ( ): percent change from baseline within the group. NA = not assessed. 1) prot +zn: Essential amino acids / whey protein with zinc
(30mg/d), n=30. 2) prot:  Essential amino acids / whey protein without zinc, n=31. 3) untreated:  Untreated control, n=8. a) 25-hydroxyvitamin D. b) 1, 25-dihydroxyvitamin D; #  p <.05:
unpaired two tailed student t-test; as compared the zinc supplemented group with the unsupplemented subjects; ## p=.0001: ANOVA for repeated measures; there is a significant increase
overtime in both groups receiving amino acids-whey protein. * p<.05, ** p<.005: ANOVA for repeated measures; it showed a significant difference between zinc supplemented and the
unsupplemented group. ‡ p<.05, ‡‡ p<.005: unpaired two tailed student t-test; as compared the zinc supplemented group with the unsupplemented subjects. § p < .05 zinc supplemented vs
unsupplemented.
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Discussion
In the present study, we investigated whether the addition of
zinc, which is known to influence IGF-I production, is able to
modify the IGF-I response to essential amino acids-whey
protein supplements in undernourished elderly patients. The
results indicate that a zinc supplement significantly accelerated
IGF-I recovery and reduced the serum levels of a biochemical
marker of bone resorption. Activities of daily living were
significantly improved by zinc supplementation in the sub-
group of patients with lower  serum albumin.
Protein malnutrition is often observed in the elderly and is
associated with a large series of morbidities, including
osteoporosis and impaired post-fracture recovery (3, 8).
Previous randomized controlled trials in recent hip fracture
patients have demonstrated that a simple oral casein protein
supplement given for periods between 5 weeks and 6 months,
that just corrected protein undernutrition, not only improved
fracture outcome (19-21, 43), but also attenuated proximal
femur bone loss (21). These findings were associated with
increased serum IGF-I levels (21). Our study confirms the
beneficial effects of oral protein supplements on IGF-I activity
in the non fractured frail elderly, with a rapid response
detectable by just one week of supplementation. This is in
agreement with previous studies that showed 5 weeks of protein
supplementation was able to significantly improve the outcome
after hip fracture (19, 20). The type of supplements we used in
the present study were based on observations of animal
experiments, in which essential amino acid supplements were
able to increase bone strength, to improve microarchitecture
and intrinsic bone tissue quality (13). This was observed in
adult rats receiving an isocaloric low protein diet, a situation
reminiscent of the conditions of the frail elderly investigated in
the current trial. 
Zinc insufficiency is highly common in the elderly and may
contribute to a frailty syndrome, possibly through an effect on
IGF-I production and/or action (24, 27, 28). We thus performed
the present study in order to assess the hypothesis that zinc
could magnify the circulating levels and actions of IGF-I and
the functional response to protein repletion. Plasma zinc
measurements may not be the reflection of body stores because
most of the body zinc stores are intracellular. Hence, mild zinc
insufficiency can occur with low but still in the normal range
plasma levels. At baseline, both groups had a zinc serum
concentration at the lower limit of normal range. After four
weeks, it remained stable in the non supplemented group,
whilst an increase of close to 60% was observed in the group
receiving zinc (Table 2). Our results indicate that the increase
in serum IGF-I levels induced by protein supplements was
accelerated, with a significant difference detectable after only
one week of zinc addition. This could represent a clinically
relevant advantage, since the potential benefits of correcting
low IGF-I concentration could be achieved at a very early stage
of intervention. A rapid improvement would be particularly
desirable in the phase of recovery after surgery or in the
rehabilitation phase of undernourished elderly. By 4 weeks of
protein supplements, however, there was no further advantage
of zinc supplementation.
Previous studies in humans and in animals have
demonstrated that protein deficiency is associated with an
increased bone loss and decreased bone strength (3, 12). These
modifications of bone strength are the results of a markedly
increased bone resorption and decreased bone formation. In the
present study, untreated controls showed an increase in the
bone resorption marker, CrossLapsTM, during the 4-week
observation period, whereas the values remained stable in the
group receiving the essential amino acids-whey protein
supplements. Zinc addition was associated with a significant
reduction of the bone resorption marker. At the present time,
we have no argument in favor of a direct or indirect effect of
zinc on bone turnover. In vitro experiments have shown some
inhibition of bone resorption by zinc (32, 34). However, our
experimental design does not allow one to selectively assess the
effects of zinc supplements on bone remodeling, since there
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Table 3
Changes at 28 Days in Functional Performances Variables 
EAA / whey protein EAA / whey protein Untreated controls
with zinc (30mg/d) without zinc
All alb<30g/l alb>30g/l All alb<30g/l alb>30g/l
n = 30 n=10 n=20 n=31 n=13 n=18 n=8
ADL scorea D0 10.6 (0.5) 11.6 (1.0) 10.1 (0.6) 10.5 (0.5) 10.2 (0.7) 10.8 (0.7) NA
D28 7.7 (0.3) 7.6 (0.6) 7.8 (0.4) 8.4 (0.6) 8.6 (0.9) 8.1 (0.8) NA
Percent change -27.0 (3.1)** -25.7 (8.1)* -27.4 (3.2) -18.3 (4.5)** -11.9 (6.5) -24.7 (5.5) NA
BMIb D0 22.1 (1.1) 21.8 (1.3) 22.2 (1.5) 21.7 (0.7) 21.7 (1.4) 21.8 (0.9) 26.2 (1.0) #
D28 22.7 (2.1) 22.5 (2.1) 22.8 (3.2) 21.4 (1.2) 21.4 (1.9) 21.5 (1.5) 25.7 (1.0)
Percent change -0.5 (0.7) -0.8 (1.3) -0.4 (0.9) -1.3 (0.8) -1.5 (0.8) 1.1 (1.6) -1.9 (1.5)
Hospital stay (day) 45.4 (5.7) 52.1 (7.2) 42.1 (7.8) 39.7 (4.3) 48.2 (9.0) 33.7 (3.4) 39.3 (8.8)
Values are given as the mean (SEM); EAA = Essential amino acids; NA= not assessed; alb= albumin. a. Activity of daily living according to Katz (38). This score estimates the degree of
dependency for bathing, dressing, going to the toilet, transferring from bed, continence and feeding according to a scale from 6 to 18 (with 6 as complete independence). b. Body Mass
Index [weight (kg) / height2 (m2)]. ** p=.001 (ANOVA for repeated measurement) in the two supplemented groups (with and without zinc); there is a significant increase overtime in
both groups. *  p=.006 (Wilcoxon rank test), as compared to the group without zinc supplement and with an albumin < 30g/l. # p < .05 comparing the untreated group vs the whole
supplemented group
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was an interaction with protein repletion. Additional studies are
still required to confirm this hypothesis. In preclinical studies,
essential amino acids supplements decreased bone resorption in
rats fed an isocaloric low protein diet (13). The mechanisms of
this protein effect on bone resorption have not yet been
elucidated. IGF-I is unlikely to be the only factor involved
since this growth factor acts to increase bone remodeling, as
demonstrated by significant increases in osteocalcin, and is
involved in osteoclastogenesis regulation (44). The patients
enrolled in the study were clearly undernourished as indicated
by the mini nutritional assessment score (37) and the low
values of serum albumin and IGF-I. Despite a strict
randomization procedure, there was a small difference in
vitamin D status at baseline between the zinc group and the
controls. There is likely to be a link between vitamin D and
IGF-I (45, 46); however, in our study we didn’t find any
correlation between IGF-I level and vitamin D (data not
shown). This is very unlikely to explain the IGF-I response to
zinc. Although the present study was underpowered to detect
significant changes in functional performances, we were able to
observe that in the prespecified subgroup with baseline albumin
below 30g/l, zinc addition was associated with a more
favorable evolution of ADL score. 
In conclusion, the present study has shown that protein
supplements (including whey protein and essential amino acids)
increase serum IGF-I and a bone formation marker in
undernourished elderly patients. Furthermore, we have
demonstrated that the addition of zinc to the protein
supplements accelerates the IGF-I response, and this is
accompanied by an inhibition of bone resorption. This
nutritional combination could be beneficial in the frail elderly
at risk for osteoporotic fracture.
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